We are independent & ad-supported. We may earn a commission for purchases made through our links.

Advertiser Disclosure

Our website is an independent, advertising-supported platform. We provide our content free of charge to our readers, and to keep it that way, we rely on revenue generated through advertisements and affiliate partnerships. This means that when you click on certain links on our site and make a purchase, we may earn a commission. Learn more.

How We Make Money

We sustain our operations through affiliate commissions and advertising. If you click on an affiliate link and make a purchase, we may receive a commission from the merchant at no additional cost to you. We also display advertisements on our website, which help generate revenue to support our work and keep our content free for readers. Our editorial team operates independently from our advertising and affiliate partnerships to ensure that our content remains unbiased and focused on providing you with the best information and recommendations based on thorough research and honest evaluations. To remain transparent, we’ve provided a list of our current affiliate partners here.

What Is DDAVP® Nasal Spray?

By Andy Josiah
Updated Mar 03, 2024
Our promise to you
The Health Board is dedicated to creating trustworthy, high-quality content that always prioritizes transparency, integrity, and inclusivity above all else. Our ensure that our content creation and review process includes rigorous fact-checking, evidence-based, and continual updates to ensure accuracy and reliability.

Our Promise to you

Founded in 2002, our company has been a trusted resource for readers seeking informative and engaging content. Our dedication to quality remains unwavering—and will never change. We follow a strict editorial policy, ensuring that our content is authored by highly qualified professionals and edited by subject matter experts. This guarantees that everything we publish is objective, accurate, and trustworthy.

Over the years, we've refined our approach to cover a wide range of topics, providing readers with reliable and practical advice to enhance their knowledge and skills. That's why millions of readers turn to us each year. Join us in celebrating the joy of learning, guided by standards you can trust.

Editorial Standards

At The Health Board, we are committed to creating content that you can trust. Our editorial process is designed to ensure that every piece of content we publish is accurate, reliable, and informative.

Our team of experienced writers and editors follows a strict set of guidelines to ensure the highest quality content. We conduct thorough research, fact-check all information, and rely on credible sources to back up our claims. Our content is reviewed by subject matter experts to ensure accuracy and clarity.

We believe in transparency and maintain editorial independence from our advertisers. Our team does not receive direct compensation from advertisers, allowing us to create unbiased content that prioritizes your interests.

DDAVP® Nasal Spray is a trade name of desmopressin, a synthetic analog of vasopressin. This is a naturally occurring hormone responsible for reducing the volume of urine. The DDAVP® Nasal Spray trade name is used by pharmaceutical company Sanofi-aventis U.S., although there are other trade names for desmopressin, which include Stimate and Minirin.

Since DDAVP® Nasal Spray is used for reducing urination to control the body’s water balance, it is classified as an antidiuretic. It is manufactured as a spray in a 5-milliliter (mL) bottle with compression pump, designed for administering to the nose 0.1 mL at a time. Each pump delivers 0.1 milligrams of desmopressin acetate, which is its salt form, or desmopressin derived from the organic compound of acetic acid. Other chemicals that DDAVP® Nasal Spray contains include sodium chloride, citric acid monohydrate, disodium phosphate dihydrate and benzalkonium chloride.

An increase in urination is a primary indication of diabetes insipidus (DI). This is caused by the deficiency of vasopressin. The urine increase vasopressin causes is in its dilution or water component, thereby decreasing its concentration. DDAVP® Nasal Spray is specifically used for one of the two types of DI known as central diabetes insipidus, which concerns vasopressin deficiency. The treatment is not effective for the other type, nephrogenic DI, which is caused by a lack of response of the kidneys to vasopressin.

DDAVP® Nasal Spray is also used for nocturnal enuresis, since it concerns urination. People with nocturnal enuresis involuntarily urinate when they are asleep, specifically at night. This condition is more commonly known as bed wetting. Besides urinary disorders, DDAVP® Nasal Spray is applied to people with blood-related ailments such as hemophilia and von Willebrand's disease.

Adults have a dosage range of 0.1 to 0.4 mL per day, which can constitute one dose or be split into two or three doses. The most common dose, however, is 0.2 mL split into two doses. A daily dosage range of 0.05 to 0.3 mL is recommended for people between the age of 3 months and 12 years, either in a single dose or two doses.

People who have a history of medical conditions such as coronary artery insufficiency, hypertensive cardiovascular disease or cystic fibrosis should use DDAVP® Nasal Spray with caution. Also, side effects such as scarring and fluid accumulation can occur in the nose. The United States Food and Drug Administration (FDA) places DDAVP® Nasal Spray in the relatively mild pregnancy category B of its classification system of pharmaceutical fetal risk.

The Health Board is dedicated to providing accurate and trustworthy information. We carefully select reputable sources and employ a rigorous fact-checking process to maintain the highest standards. To learn more about our commitment to accuracy, read our editorial process.

Discussion Comments

The Health Board, in your inbox

Our latest articles, guides, and more, delivered daily.

The Health Board, in your inbox

Our latest articles, guides, and more, delivered daily.